High Tech

In May 2026, High Tech’s mix concentrated heavily in Flower at 89.59% share, with Vapor Pens at 6.33% and Concentrates and Pre-Roll at 2.84% and 1.25% respectively; within that mix, Flower fell 53.06% year over year and 36.61% month over month, while Vapor Pens declined 82.50% year over year and 42.14% month over month. Concentrates contracted 84.16% year over year but only 8.62% month over month, and Pre-Roll dropped 80.05% year over year and 24.92% month over month; against this category backdrop, overall brand sales were down 60.19% year over year while the average price rose 35.36%, and the Flower rank in Oregon stood at 27. The concentration in Flower alongside deeper declines in Vapor Pens and Pre-Roll implies a narrowing product strategy that is amplifying exposure to Flower volatility rather than diversifying revenue stability.

With Flower anchoring nearly nine-tenths of revenue and posting a 36.61% month-over-month decline as Vapor Pens fell 42.14% month over month, the current mix points to price-led rather than mix-led value capture, given a 35.36% year-over-year average price increase alongside a 60.19% year-over-year sales contraction. The relatively smaller month-over-month drop in Concentrates at 8.62% versus Pre-Roll at 24.92% indicates a potential buffer category that is underweight at 2.84% share, while the 27 rank in Oregon Flower combined with an 82.50% year-over-year decline in Vapor Pens suggests the brand’s position is tied to mid-pack Flower execution rather than breadth across inhalables. This pattern implies that modest re-weighting toward Concentrates and selective Pre-Roll can reduce dependence on a single category while preserving price architecture, whereas maintaining the current mix is likely to keep rank capped in Flower and leave total sales sensitive to single-category shocks.